EICHOR
● Recruiting
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Condition: Solid Tumor · Sponsor: Miller Children's & Women's Hospital Long Beach
About this study
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is then treated with ad hoc regimens or early phase therapies with little benefit to the patient. Metronomic therapy (MC), defined as lower dose continuous drug exposure, has been successfully tested in pediatric leukemias with excellent results in terms of improved outcome, toxicity profiles, and cost. MC has been applied to solid tumors with little success, but has been implemented usually in the relapsed setting at a time of high tumor burden and disease resistance.
This description comes directly from the study's public registry record.
Talk to the study team
Ted Zwerdling, MD · 562-933-8600 · tzwerdling@memorialcare.org
Devin Murphy, MSW · 562-933-8601 · dmurphy@memorialcare.org
Always discuss trial participation with your own doctor first.
Locations (2)
| Miller Children's and Women's Hospital Long Beach | Long Beach, California, United States | Recruiting |
| Children's Hospital Orange County | Orange, California, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02446431